Oxandrolon 10mg/tab 100 Tabletten by Balkan Pharmaceuticals

Usage

1. Determine your starting dose based on prior AR-active compound experience; first-time users should begin at 10 mg/day to assess individual receptor sensitivity before titrating.
2. Administer tablets orally with water, ideally at consistent times relative to meals — the lipophilic nature of DHT-derived compounds means moderate dietary fat can support absorption.
3. If using more than 20 mg/day, divide the daily dose across two administrations (morning and early afternoon) to maintain steadier plasma concentrations across Oxandrolone's ~9–10 hour half-life.
4. Do not crush or dissolve tablets; the compressed matrix is calibrated for the HPLC-verified 10 mg dose and should be swallowed intact to ensure uniform delivery.
5. Log daily dose, timing, and subjective indicators (strength, recovery, appetite) to correlate with the compound's AR-mediated genomic effects — genomic AR signalling has a lag of 24–72 hours before downstream protein synthesis changes become measurable.
6. Schedule ALT and AST liver enzyme tests at the midpoint and end of the cycle; the 17α-methyl group that ensures oral bioavailability also generates hepatic load that must be tracked throughout use.

Warnings

Frequently asked questions

How does Oxandrolone bind to the androgen receptor compared to testosterone?

Oxandrolone binds the androgen receptor with a relative binding affinity roughly 3–5 times higher than testosterone in competitive in-vitro assays, because it is already a DHT analogue and requires no enzymatic conversion before engaging the receptor's ligand-binding domain. This direct, high-affinity interaction allows meaningful anabolic signalling at lower absolute doses, which is one reason 10–20 mg/day produces measurable nitrogen-retention effects in clinical literature.

Why can't Oxandrolone convert to estrogen at the androgen receptor level?

The inability to aromatise is structural, not pharmacological: Oxandrolone's A-ring carries a 2-oxa substitution that sterically prevents aromatase from catalysing the conversion to an estrogen product. Because the enzyme's active site cannot accommodate the modified ring, no estradiol is produced regardless of dose — making estrogenic water retention mechanistically impossible without a separate aromatisable compound in the stack.

What androgen response elements does Oxandrolone-activated AR target in muscle tissue?

After nuclear translocation, the AR complex occupied by Oxandrolone binds androgen response elements in the promoter regions of genes encoding myosin heavy chain isoforms and IGF-1 splice variants in skeletal muscle. Simultaneously, it suppresses FOXO-mediated atrogene expression (MuRF-1, Atrogin-1), shifting the transcriptional balance toward protein synthesis and away from muscle protein breakdown — a dual genomic effect documented in both rodent myotube models and human wasting-disease trials.

What is the advantage of Balkan Pharmaceuticals' 10mg tablet format for dose titration?

The 10 mg/tablet concentration is the lowest unit dose in Balkan's Oxandrolone range, making it the most granular tool for incremental dose adjustment. Users can move from 10 mg/day up to 40 mg/day in precise 10 mg steps without splitting pills, preserving tablet-matrix integrity and ensuring the full HPLC-verified dose is delivered. The 100-tablet blister pack also allows cycle planning without needing multiple purchases for shorter protocols.

Can Balkan Pharmaceuticals Oxandrolon 10mg tablets be split for sub-10mg dosing?

Splitting is physically possible but not recommended as a standard practice, because the tablet compression matrix is not scored, and bisection may produce unequal halves, altering the effective dose per administration. For sub-10 mg dosing needs, consulting a healthcare professional about the appropriate formulation is the preferred approach. For most clinical and performance protocols cited in the literature, 10 mg remains the established minimum effective dose unit. (2) angle_used

Manufacturer

Oxandrolon occupies a specific position within Balkan Pharmaceuticals' oral tablet catalogue — one that illustrates the company's founding commitment, articulated at its 2006 launch in Chișinău, Moldova, to build analytical accountability into tablet manufacturing rather than treating quality as an afterthought. The oral production line at the Chișinău facility operates under GMP certification conditions, with each Oxandrolon batch progressing through a defined release sequence: raw API identity testing on intake, in-process tablet weight uniformity checks during compression, and post-compression HPLC assay to confirm that active Oxandrolone content matches the declared 10 mg per tablet within validated acceptance criteria. LAL (Limulus Amebocyte Lysate) endotoxin screening — a method typically associated with injectable production — is applied as an additional quality checkpoint, reflecting the company's policy of applying pharmaceutical-grade release standards across its entire portfolio rather than limiting rigorous testing to its ampoule range. Balkan Pharmaceuticals' analytical infrastructure is not outsourced: the QC laboratory integrated into the Chișinău site is the same facility that generates the batch release certificates accompanying each SKU through the authorised distribution network.